Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
  • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/18—Feminine contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/36—Antigestagens
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
  • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
  • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
  • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Definitions

• the invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives of the formula I having progesterone antagonizing action and a process for their preparation, their use for the treatment and / or prophylaxis of diseases and their use for the manufacture of medicaments for the treatment and / or prophylaxis of diseases, in particular uterine fibroids (fibroids, uterine leiomyomas), endometriosis, severe menstrual bleeding, meningiomas, hormone-dependent breast cancers and menopausal-related disorders or for fertility control and emergency contraception.
• uterine fibroids fibroids, uterine leiomyomas
• endometriosis severe menstrual bleeding, meningiomas, hormone-dependent breast cancers and menopausal-related disorders or for fertility control and emergency contraception.
• these compounds are valuable pharmaceutical agents. They may be used, inter alia, for the preparation of pharmaceutical preparations for the treatment of uterine fibroids or endometriosis, severe menstrual bleeding, meningiomas, hormone-dependent breast cancers and menopausal-related disorders or for fertility control and emergency contraception.
• the compounds according to the invention can also be administered sequentially in combination with progestins.
• the compounds of the present invention could be given over a period of 1-6 months, followed by a treatment break or a sequential treatment with a progestogen over a period of 2-6 weeks or followed by treatment with an oral contraceptive (OC). Combinations) over the same period.
• the efficacy of the compounds of the invention as a progesterone receptor antagonist has been demonstrated in vitro in transactivation assays and in vivo in rats (early pregnancy termination).
• Compounds with antagonistic action on the progesterone receptor are first known in 1982 (RU 486, EP57115) and have since been extensively described.
• Progesterone receptor antagonists with fluorinated 17 ⁇ -side chain have been identified in WO 98/34947 and Fuhrmann et al., J. Med. Chem. 43, 5010-5016 (2000 ) released.
• Object of the present invention is to provide highly potent competitive progesterone receptor antagonists available and thus to provide alternative treatment options for gynecological diseases.
• compounds according to the invention are particularly suitable for achieving this object.
• compounds having alkylsulfanyl and alkylsulfonyl groups show a very strong antagonistic activity on the progesterone receptor, i. they inhibit the action of progesterone on its receptor.
• the compounds having alkylsulfonyl groups were compared by e.g. to the alkanoyl groups have a significantly higher metabolic but also chemical stability to temperature, light and oxidative stress.
• the compound shows (11 ⁇ , 17 ⁇ ) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one (Example 4) compared to the respective analog with an alkanoyl or hydroxyalkanoyl group (11 ⁇ - (4-acetylphenyl) -20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17 ⁇ -pregna-4,9-dien-3-one or 20,20,21,21,21-pentafluoro-17-hydroxy-11 ⁇ - [4- (hydroxyacatyl) phenyl] -19-nor-17 ⁇ -pregna-4,9-dien-3-one
• the compounds of the general formula I according to the invention can exist in stereoisomeric forms (enantiomers, diastereomers).
• the invention therefore includes the enantiomers or diastereomers and their respective mixtures including the racemates. From such mixtures of enantiomers and / or diastereomers, the stereoisomerically uniform components can be isolated in a known manner.
• Each of said substituents on the steroid backbone may be present in both an ⁇ and a ⁇ position.
• the substituents on the steroid backbone which contain a double bond and in which the double bond on each atom carries at least one non-hydrogen substituent may also be both E- and Z-configured.
• the present invention encompasses all tautomeric forms.
• Salts used in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. But are also included salts for pharmaceutical Applications themselves are not suitable but can be used for example for the isolation or purification of the compounds of the invention.
• Physiologically acceptable salts of the compounds of the invention comprise, when a basic function is included, salts with inorganic or organic acids, especially mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, ethanesulfonic, toluenesulfonic, benzenesulfonic, naphthalenedisulfonic, acetic, trifluoroacetic, propionic, lactic, tartaric, malic, citric, fumaric, maleic and benzoic acids.
• salts of hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, ethanesulfonic, toluenesulfonic, benzenesulfonic, naphthalenedisulfonic acetic, trifluoroacetic, propionic, lactic, tartaric, malic, citric, fum
• Physiologically acceptable salts of the compounds of the invention include, when containing an acidic function, alkali metal salts, alkaline earth metal salts or ammonium salts, such as may be obtained by reaction with corresponding inorganic or organic bases.
• alkali metal salts for example sodium and potassium salts
• alkaline earth salts for example calcium and magnesium salts
• ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms such as, for example and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine , Monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine, N-methylpiperidine, N-methyl-glucamine, D-methyl-glucamine, eth
• Solvates in the context of the invention are those forms of the compounds according to the invention which, in the solid or liquid state, show adduct formation with solvent molecules.
• the solvent may be present in a stoichiometric or unstoichiometric ratio.
• Stoichiometric solvates are also known as hemi, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta-, etc. solvates. Hydrates are a special form of solvates that coordinate with water.
• radicals are substituted in the compounds according to the invention, the radicals can, unless otherwise specified, be monosubstituted or polysubstituted. In the context of the present invention, the meaning is independent of each other for all radicals which occur repeatedly. Substitution with one, two or three identical or different substituents is preferred. Very particular preference is given to the substitution with a substituent.
• R 1 is S (O) 2 R 3
• X is O
• R 3 is C 1 -C 6 -alkyl, in particular those in which R 3 is methyl.
• radical definitions given in detail in the respective combinations or preferred combinations of radicals are also replaced, irrespective of the particular combinations of the radicals indicated, by radical definitions of other combinations.
• the compounds of the general chemical formula I are prepared from (5'R, 8'S, 10'R, 13'S, 14'S, 17'S) -5,5,13'-trimethyl-1 ', 2', 7 ', 8 ', 12', 13 ', 14', 15 ', 16', 17'-decahydro-6'H-spiro [1,3-dioxane-2,3 '- [5,10] epoxycyclopenta [a] phenanthrene] -17'-ol (preparation see Tetrahedron Lett. 26, 2069-2072 (1985 ) in analogy to those in WO 98/34947 and in WO 2008/058767 described method.
• a biphenyl radical is located in the 11 ⁇ position of the steroid skeleton this either directly by conjugated addition of Diarylgrignard- or Diaryllithiumreagenzes under copper catalysis or, for example via palladium-catalyzed coupling reactions to the correspondingly functionalized 11 ⁇ -phenyl derivatives, eg phenyl triflates or Phenylnonaflate done.
• both the 11 ⁇ -phenyl radical and the 17 ⁇ -pentafluoroethyl side chain can be introduced first.
• Functional groups, especially the 3-keto group may be protected in the meantime, eg as ketal.
• Ketalschutz tendency are for example the ethylenedioxy or the 2,2-dimethylpropylene-1,2-dioxy distr mentioned.
• hydroxy groups are protected in the form of methoxymethyl, methoxyethyl, tetrahydropyranyl, benzyl, or silyl ethers.
• isomer mixtures can be separated into the individual compounds by customary methods, such as, for example, crystallization, chromatography or salt formation.
• the preparation of the salts is carried out in a customary manner by adding a solution of the compound of the general formula I with the equivalent amount or an excess of a base or acid, optionally in solution, optionally separating the precipitate or in the usual way the solution works up.
• the resulting compounds of formula (I) are optionally reacted with the appropriate (i) solvents and / or (ii) bases or acids to their solvates, salts and / or solvates of the salts.
• the compounds of the invention show an unpredictable, valuable pharmacological, pharmacokinetic and pharmacodynamic profile of action.
• the pharmaceutical activity of the compounds according to the invention can be explained by their action as progesterone receptor antagonists, ie their antagonizing action on the progesterone receptor.
• Another object of the present invention is the use of the compounds of the invention for the treatment and / or prophylaxis of diseases based on hormone-dependent hyperproliferative processes, preferably of gynecological diseases, in particular uterine fibroids, endometriosis or hormone-dependent breast carcinomas.
• Another object of the present invention is the use of the compounds of the invention for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
• Another object of the present invention are the compounds of the invention for use in a method for the treatment and / or prophylaxis of uterine fibroids, endometriosis and hormone-dependent breast carcinomas.
• Another object of the present invention is the use of the compounds of the invention for the manufacture of a medicament for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
• Another object of the present invention is a method for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases, using 0.1-100 mg of the compounds of the invention per day and patient in the treatment of uterine fibroids or endometriosis and for the Contraceptive application or from 0.1-500 mg of the compounds of the invention per day and patient in tumor diseases (eg Menginiome or hormone-dependent tumors such as breast cancer) and in emergency contraception.
• tumor diseases eg Menginiome or hormone-dependent tumors such as breast cancer
• Another object of the present invention are pharmaceutical compositions containing at least one compound of the invention and at least one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
• drugs / classes of drugs are administered either simultaneously or sequentially: SERMs, SERDs, antiestrogens, aromatase inhibitors, kinase inhibitors, angiogenesis inhibitors and / or cytostatics.
• the compounds according to the invention can be combined simultaneously or sequentially with gestagens or combinations of estrogens and gestagens.
• progesterone receptor antagonists / progestin regime disclosed in WO 96/15794 (Spicer et al., Balance Pharm. Inc.), WO 96/03130 (Stöckemann et al., Schering AG) and PCT / EP2009 / 003249 (Moeller et al. , Bayer Schering Pharma AG) are progesterone receptor antagonists / progestin regime disclosed.
• Well suited for the treatment of uterine fibroids and endometriosis are - optionally repeating - regimens in which the progesterone receptor antagonist is given over a period of two to four months, followed by administration of the progestogen over a period of one to four weeks.
• Particularly suitable is the - optionally repeated - 84-day administration of the progesterone receptor antagonist followed by the 14-day administration of the gestagen.
• SERMs Selective Estrogen Receptor Modulators are those compounds which have either an antiestrogenic or estrogenic effect on the tissue, for example inhibiting the action of the estrogen on the uterus but having a neutral or estrogen-like effect on the bone. Examples are clomifene, raloxifene, tamoxifen, torimifene, apeledoxifene, lasofoxifene and ormeloxifene.
• SESD Selective Estrogen Receptor Stabilizers
• Antiestrogens are compounds which completely antagonize the estrogen receptor, for example fulvestrant.
• Aromatase inhibitors inhibit the enzyme aromatase and thus the aromatization of androgens in estrogens. These include u.a. Anastrozole, Letrozole, Exemestane, Vorozole, Formestane and Fadrozole.
• Kinase inhibitors are enzymes which transfer a phosphate residue from ATP to other substrates, especially to hydroxy groups, e.g. Sorafenib (Nexavar) or Imatinib (Gleevec).
• Angiogenesis inhibitors e.g. Avastin, reduce or block the vascular supply and thus the blood flow to a tumor.
• Cytostatics e.g. cis-Platin, Taxol, Taxotere are natural or synthetic substances that inhibit cell growth or cell division.
• progestins are understood to be either the natural progesterone itself or synthetic derivatives which, like the progesterone itself, bind to the progesterone receptor and inhibit ovulation in dosages which are above the ovulation inhibitor dose.
• synthetic derivatives include drospirenone, gestodene, levonorgestrel, cyproterone acetate, desogestrel and 3-ketodesogestrel, norethisterone, norethisterone acetate and dienogest.
• Combinations of progestogens and estrogens are the active ingredient combinations contained in the conventional oral contraceptives, for example, Yasmin, Femovan, Triquilar, Marvelon, YAZ, etc.
• the compounds according to the invention can act systemically and / or locally.
• they may be suitably administered, such as orally, intrauterine [ins], intravaginal, parenteral, pulmonary, nasal, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally, otically or as an implant or stent.
• Intrauterine [är] means in particular the application by means of IUS (intrauterine system) or IUD (intrauterine device).
• the intravaginal application can i.a. by IVR / VRS (intra vaginal ring / vaginal ring system).
• Intrauterine or intravaginal application forms see, eg WO 01/47490 , in particular page 1, line 10 to page 5, line 13 and page 7, line 19 to page 58, line 6, or for vaginal rings: WO 06/010097 , in particular page 10, line 22 to page 14, line 28), the compounds according to the invention and nonsilicone and / or silicone polymers, in particular also siloxane-based elastomers (cf. WO 01/47490 , especially page 7, line 19 - page 15, line 15).
• the compounds according to the invention can be administered in suitable administration forms.
• Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
• a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
• absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally.
• parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
• Inhalant medicines including powder inhalers, nebulizers
• nasal drops solutions, sprays
• lingual, sublingual or buccal tablets films / wafers or capsules
• suppositories ear or ophthalmic preparations
• vaginal capsules aqueous suspensions (lotions, shake mixtures)
• lipophilic suspensions ointments
• creams transdermal therapeutic systems (such as patches)
• milk Pastes, foams, scattering powders, implants or stents.
• the compounds according to the invention can be converted into the stated administration forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
• excipients include excipients (for example, microcrystalline cellulose, lactose, mannitol), solvents (eg, liquid polyethylene glycols), Emulsifiers and dispersing or wetting agents (for example sodium dodecylsulfate, polyoxysorbitanoleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (for example antioxidants such as ascorbic acid), dyes (for example inorganic pigments such as, for example, iron oxides) and flavorings / or scent remedies.
• Another object of the present invention are pharmaceutical compositions containing at least one compound of the invention, usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
• reaction mixture was allowed to come to 23 ° C with stirring over about 3 hours and then stirred at this temperature for 10 hours.
• saturated aqueous NH 4 Cl solution was added to the reaction mixture with external cooling.
• the mixture was stirred for a further 30 minutes and then extracted several times with ethyl acetate.
• the combined organic phases were washed with saturated sodium chloride solution and dried over sodium sulfate.
• the crude product was purified by chromatography on silica gel followed by crystallization from a mixture of dichloromethane and diisopropyl ether. 5.72 g of the title compound were obtained.
• Example 1b Analogously to Example 1b) were prepared from 3 g of the compound described under 1a), 888 mg of magnesium turnings, 91 mg of CuCl and 7.94 g of 1-bromo-4- (ethylthiopheny) benzene in THF 2.7 g of the title compound.
• Example 1c 125 mg of the title compound were prepared from 200 mg of the compound prepared under 2a) by reaction with half-concentrated sulfuric acid in methanol.
• Example 4 Analogously to Example 4, were obtained 183 mg of the title compound by reacting 400 mg of the compound described under Example 2a) with 1.56 g of Oxone ® in a mixture of 10 ml THF and 10 ml of methanol, after purification by chromatography on silica gel.
• Example 6a Analogously to Example 1c), 1.62 g of the compound prepared under Example 6a) were prepared by reaction with half-concentrated sulfuric acid in methanol to give 1.02 g of the title compound.
• Example 1c Analogously to Example 1c), from 2.72 g of the compound prepared under 7b), 2.2 g of the title compound were prepared by reaction with half-concentrated sulfuric acid in methanol.
• Example 9d Analogously to Example 9d) were prepared from 500 mg of the under Example 9c) and (4-methylsulfonylphenyl) boronic acid in the presence of tetrakis (triphenylphosphine) palladium, lithium chloride, 2 molar aqueous sodium carbonate solution in a mixture of toluene and ethanol, 256 mg of the title compound.
• Example 1c Analogously to Example 1c), 62 mg of the title compound were prepared from 110 mg of the compound prepared under 10a) by reaction with half-concentrated sulfuric acid in methanol.
• Example 7b Analogously to Example 7b), 638 mg of the title compound were obtained from 709 mg of the compound obtained under Example 11a) by reaction with 30% strength hydrogen peroxide solution and sodium carbonate in a mixture of acetonitrile and methanol.
• tetrakis triphenylphosphine
• Example 9d Analogously to Example 9d) were from 300 mg of the compound described in Example 9c) and [4 - [(dimethylamino) sulfonyl] phenyl] boronic acid in the presence of tetrakis (triphenylphosphine) palladium, lithium chloride, 2 molar aqueous sodium carbonate solution in a mixture of toluene and Ethanol 235 mg of the title compound.
• triphenylphosphine triphenylphosphine
• Example 1c 113 mg of the title compound were prepared from 230 mg of the compound prepared under 14a) by reaction with half-concentrated sulfuric acid in methanol.
• Example 1c Analogously to Example 1c), from 100 mg of the compound prepared under 15a), by reaction with half-concentrated sulfuric acid in methanol, 74 mg of the title compound were prepared.
• Example 16 Progesterone Receptor Antagonist Activity in Stable Transfectants of Human Neuroblastoma Cells (SK-N-MC Cells) with the Human Progesterone A or Progesterone B Receptor and an MTV-LUC Reporter Construct
• progesterone and the progesterone receptor are essential for successful pregnancy or gestation in mammals.
• the animals were then subcutaneously orally each 0.15; 0.5; 1.5 or 5 mg / kg of the test compound or 1.0 ml / kg of vehicle (benzyl benzoate / castor oil: 1 + 4 [v / v]) daily from day 5 to day 7 (d5-d7 p.c.).
• the autopsy was performed on day 9 (d9 pc). As a parameter of the progesterone receptor antagonistic effect of the uterus was examined for the presence of Nidationsstellen. The complete absence, but also the presence of pathological, haemorrhagic or otherwise abnormal sites of nidation on day 9 (d9 pc) was considered abortion. The results of the tests are shown in Table 3. Tab.
• Example 1 (11 ⁇ , 17 ⁇ ) -17-hydroxy-11- [4- (methylsulfanyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one 0.5 80 1.5 100 5.0 100
• Example 4 (11 ⁇ , 17 ⁇ ) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one 0.15 40 0.5 100 1.5 100 5.0 100
• Example 8 (11 ⁇ , 17 ⁇ ) -17-hydroxy-11- [4- (RS-methylsulfonimidoyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one 0.15 40 0.5 100 1.5 100 5.0 100
• Example 18 Metabolic Stability of (11 ⁇ , 17 ⁇ ) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one and (11 ⁇ , 17 ⁇ ) - 17-hydroxy-11- [4 '- (methylsulfonyl) -biphenyl-4-yl] -17- (pentafluoroethyl) estra-4,9-dien-3-one in human liver microsomes (HLM)
• HBM human liver microsomes
• Example 19 Permeation of (11 ⁇ , 17 ⁇ ) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-dien-3-one in Caco-2 cells.
• the Caco2 cells with a cell count of 300,000 cells / ml were placed on Transwell Clear filter inserts (polyester, pore size 0.4 ⁇ m) in a 12-well cell culture plate for at least 14 days in cell culture medium (1.5 ml) at 37 ° C, 5% CO2 and cultivated 95% humidity.
• the transepithelial resistance (TEER value) which must be greater than 300 ⁇ cm 2 , was determined to check the "tightness" of the cell monolayer.
• the permeability test was carried out in duplicate at a substance concentration of 2 ⁇ M.
• 100 ⁇ l (Ap0min) was removed from the apical compartment and immediately mixed with 100 ⁇ l of ice-cold stop solution.
• the filters were then incubated at 37 ° C with gentle shaking for 90 min, then again 100 ul from the apical side (Ap90min) and 400 ul removed from the basolateral side (Bas90min) and treated with equal volume stopper solution. After further dilution of the samples with 4 times the volume Stopplsg./Transportpuffer (1 + 1) they were precipitated overnight at -20 ° C and the supernatant measured by LCMS / MS analytically.
• Papp V res A ⁇ C t 0 .
• Don • ⁇ C res ⁇ t V res buffer volume on the receptor side;
• A: filter area 1 cm 2 ;
• C t0, don substance concentration on the donor side;
• ⁇ C res / ⁇ t change in substance concentration over time on the receptor side (11 ⁇ , 17 ⁇ ) -17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoroethyl) estra-4,9-diene-3

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Epidemiology (AREA)
• Gynecology & Obstetrics (AREA)
• Diabetes (AREA)
• Pregnancy & Childbirth (AREA)
• Steroid Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Related Parent Applications (4)

Publications (1)

Family

ID=43383964

Family Applications (4)

Family Applications Before (1)

Family Applications After (2)

Country Status (48)

Families Citing this family (16)

Citations (5)

Family Cites Families (39)

• 2009
  • 2009-07-20 DE DE102009034362A patent/DE102009034362A1/de not_active Withdrawn
• 2010
  • 2010-07-07 EP EP10735198A patent/EP2432798B1/fr active Active
  • 2010-07-07 HU HUE17176264A patent/HUE043757T2/hu unknown
  • 2010-07-07 SI SI201030255T patent/SI2432798T1/sl unknown
  • 2010-07-07 DK DK12194455.7T patent/DK2623510T3/en active
  • 2010-07-07 ES ES17176264T patent/ES2730209T3/es active Active
  • 2010-07-07 LT LTEP17176264.4T patent/LT3252069T/lt unknown
  • 2010-07-07 TR TR2019/08600T patent/TR201908600T4/tr unknown
  • 2010-07-07 LT LTEP12194455.7T patent/LT2623510T/lt unknown
  • 2010-07-07 ME MEP-2019-131A patent/ME03400B/fr unknown
  • 2010-07-07 SI SI201031890T patent/SI3252069T1/sl unknown
  • 2010-07-07 JP JP2012520921A patent/JP5795312B2/ja not_active Expired - Fee Related
  • 2010-07-07 PL PL10735198T patent/PL2432798T3/pl unknown
  • 2010-07-07 EP EP17176265.1A patent/EP3272763A1/fr not_active Withdrawn
  • 2010-07-07 HU HUE12194455A patent/HUE037339T2/hu unknown
  • 2010-07-07 PT PT17176264T patent/PT3252069T/pt unknown
  • 2010-07-07 PT PT121944557T patent/PT2623510T/pt unknown
  • 2010-07-07 ES ES10735198T patent/ES2416461T3/es active Active
  • 2010-07-07 EP EP17176264.4A patent/EP3252069B1/fr active Active
  • 2010-07-07 KR KR1020127001509A patent/KR101687853B1/ko active IP Right Grant
  • 2010-07-07 DK DK10735198.3T patent/DK2432798T3/da active
  • 2010-07-07 PL PL17176264T patent/PL3252069T3/pl unknown
  • 2010-07-07 PL PL12194455T patent/PL2623510T3/pl unknown
  • 2010-07-07 US US13/376,512 patent/US20120149670A1/en not_active Abandoned
  • 2010-07-07 ME MEP-2013-69A patent/ME01534B/me unknown
  • 2010-07-07 MX MX2012000930A patent/MX2012000930A/es active IP Right Grant
  • 2010-07-07 AU AU2010275849A patent/AU2010275849B2/en not_active Ceased
  • 2010-07-07 SI SI201031582T patent/SI2623510T1/sl unknown
  • 2010-07-07 UA UAA201201277A patent/UA106502C2/uk unknown
  • 2010-07-07 WO PCT/EP2010/004149 patent/WO2011009531A2/fr active Application Filing
  • 2010-07-07 NO NO12194455A patent/NO2623510T3/no unknown
  • 2010-07-07 ES ES12194455.7T patent/ES2648292T3/es active Active
  • 2010-07-07 NZ NZ623417A patent/NZ623417A/en not_active IP Right Cessation
  • 2010-07-07 KR KR1020167020690A patent/KR101854059B1/ko active IP Right Grant
  • 2010-07-07 BR BR112012001344A patent/BR112012001344B8/pt not_active IP Right Cessation
  • 2010-07-07 IN IN598DEN2012 patent/IN2012DN00598A/en unknown
  • 2010-07-07 SG SG2012000725A patent/SG177519A1/en unknown
  • 2010-07-07 MA MA34552A patent/MA33445B1/fr unknown
  • 2010-07-07 NZ NZ597639A patent/NZ597639A/en not_active IP Right Cessation
  • 2010-07-07 PT PT107351983T patent/PT2432798E/pt unknown
  • 2010-07-07 PE PE2016002208A patent/PE20170084A1/es unknown
  • 2010-07-07 RS RS20130259A patent/RS52811B/en unknown
  • 2010-07-07 SG SG10201404159VA patent/SG10201404159VA/en unknown
  • 2010-07-07 EA EA201301263A patent/EA025150B1/ru not_active IP Right Cessation
  • 2010-07-07 EP EP12194455.7A patent/EP2623510B1/fr active Active
  • 2010-07-07 CR CR20170091A patent/CR20170091A/es unknown
  • 2010-07-07 DK DK17176264.4T patent/DK3252069T3/da active
  • 2010-07-07 CN CN201080032941.3A patent/CN102482317B/zh active Active
  • 2010-07-07 CA CA2768407A patent/CA2768407C/fr active Active
  • 2010-07-07 SG SG10201811830PA patent/SG10201811830PA/en unknown
  • 2010-07-07 MY MYPI2012000105A patent/MY179447A/en unknown
  • 2010-07-07 EA EA201200121A patent/EA021946B1/ru not_active IP Right Cessation
  • 2010-07-07 PE PE2012000076A patent/PE20121085A1/es active IP Right Grant
  • 2010-07-09 TW TW099122758A patent/TWI505830B/zh active
  • 2010-07-16 UY UY0001032791A patent/UY32791A/es not_active Application Discontinuation
  • 2010-07-18 JO JOP/2010/0255A patent/JO3009B1/ar active
  • 2010-07-20 AR ARP100102636A patent/AR077491A1/es active IP Right Grant
• 2011
  • 2011-12-13 US US13/324,912 patent/US8278469B2/en active Active
  • 2011-12-14 IL IL216967A patent/IL216967B/en active IP Right Grant
• 2012
  • 2012-01-19 TN TNP2012000028A patent/TN2012000028A1/en unknown
  • 2012-01-20 MX MX2013006080A patent/MX338217B/es unknown
  • 2012-01-20 HN HN2012000137A patent/HN2012000137A/es unknown
  • 2012-01-20 GT GT201200012A patent/GT201200012A/es unknown
  • 2012-01-20 EC EC2012011616A patent/ECSP12011616A/es unknown
  • 2012-01-20 CR CR20120040A patent/CR20120040A/es unknown
  • 2012-01-20 DO DO2012000015A patent/DOP2012000015A/es unknown
  • 2012-01-20 CU CU2012000012A patent/CU20120012A7/es active IP Right Grant
  • 2012-01-20 CL CL2012000166A patent/CL2012000166A1/es unknown
  • 2012-01-20 CO CO12008148A patent/CO6491067A2/es active IP Right Grant
  • 2012-02-17 ZA ZA2012/01222A patent/ZA201201222B/en unknown
  • 2012-11-30 HK HK12112380.9A patent/HK1171456A1/xx not_active IP Right Cessation
• 2013
  • 2013-06-18 HR HRP20130558AT patent/HRP20130558T1/hr unknown
  • 2013-06-26 CY CY20131100516T patent/CY1114260T1/el unknown
• 2015
  • 2015-05-27 JP JP2015107399A patent/JP2015178522A/ja not_active Withdrawn
  • 2015-06-04 US US14/731,232 patent/US9717739B2/en active Active
  • 2015-11-12 DO DO2015000276A patent/DOP2015000276A/es unknown
• 2016
  • 2016-03-28 JO JOP/2016/0059A patent/JO3732B1/ar active
• 2017
  • 2017-02-06 JP JP2017019347A patent/JP6130087B1/ja not_active Expired - Fee Related
  • 2017-04-04 US US15/478,803 patent/US10155004B2/en active Active
  • 2017-11-21 HR HRP20171805TT patent/HRP20171805T1/hr unknown
  • 2017-11-23 CY CY20171101228T patent/CY1119661T1/el unknown
• 2018
  • 2018-06-22 EC ECSENADI201847708A patent/ECSP18047708A/es unknown
• 2019
  • 2019-06-12 HR HRP20191049TT patent/HRP20191049T1/hr unknown
  • 2019-06-12 CY CY20191100611T patent/CY1121926T1/el unknown

Patent Citations (5)

Also Published As

Similar Documents

Legal Events